Associations between depressive symptoms, cigarette smoking, and cardiovascular health: Longitudinal results from CARDIA by Carroll, Allison J. et al.
2 
Associations between Depressive Symptoms, Cigarette Smoking, and Cardiovascular Health: 
Longitudinal Results from CARDIA 
Allison J. Carroll, PhD1,2*, Mark D. Huffman, MD MPH1, Lihui Zhao, PhD1, David R. Jacobs, PhD3, Jesse C. 
Stewart, PhD4, Catarina I. Kiefe, MD PhD5, Wendy Brunner, MS PhD6, Kiang Liu, PhD1, and Brian Hitsman, 
PhD1 
1Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago IL, 
USA 
2Department of Cardiac Surgery, Northwestern Medicine, Chicago IL, USA 
3Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, 
Minneapolis MN, USA 
4Department of Psychology, Indiana University-Purdue University Indianapolis, Indianapolis IN, USA 
5Department of Population and Quantitative Health Sciences, University of Massachusetts Medical 
School, Worcester MA, USA 
6Minnesota Department of Health, St. Paul MN, USA 
*Corresponding author: Address: 201 E Huron Street, Suite 11-250, Chicago IL 60611; Telephone: 312-
926-0568; Fax: 312-926-8208; email: acarroll@nm.org
Introduction: Depression is associated with increased risk of incident and recurrent 
cardiovascular disease, while the association between depression and cardiovascular health 
(CVH) remains unknown. Because the natural course of depression varies widely, different 
patterns of depression, as well as co-occurring factors such as cigarette smoking, may influence 
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this relationship. We examined potential interactions between longitudinal patterns of depression 
and smoking with CVH.  
Methods: Using data from the Coronary Artery Risk Development in Young Adults 
(CARDIA) study, we modeled trajectories of depression (Center for Epidemiologic Studies 
Depression Scale scores; Years 5, 10, 15, 20) and smoking (cigarettes/day; Years 0, 2, 5, 7, 10, 
15, 20). We calculated a modified American Heart Association (AHA) CVH Score (weight, 
blood glucose, cholesterol, blood pressure, physical activity, and diet; Year 20); higher scores 
indicate better CVH. Generalized linear models evaluated associations between depression 
trajectories, smoking trajectories, and their interaction with CVH Score.  
Results: The depression trajectory x smoking trajectory interaction was not associated 
with CVH Score, but main effects of depression trajectory (p<.001) and smoking trajectory 
(p<.001) were observed. Participants with patterns of subthreshold depression (β=-0.26, 
SE=0.08), increasing depression (β=-0.51 SE=0.14), and high depression (β=-0.65, SE=0.32) had 
lower CVH Scores than those without depression. Compared to never smokers, participants who 
quit smoking had higher CVH Scores (β=0.38, SE=0.11), while participants with the greatest 
smoking exposure had lower CVH Scores (β=-0.49, SE=0.22).  
Limitations: CVH Scores were adapted from the AHA guidelines based on the available 
CARDIA data. 
Conclusions: Deleterious depression and smoking trajectories are independently but not 
synergistically associated with worse CVH. 
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Depression is linked to increased risk for incident and recurrent cardiovascular disease (CVD), 
and adults with a history of depression or elevated depressive symptoms have up to two times greater 
odds of developing ischemic heart disease or suffering a fatal or nonfatal cardiac event (Van der Kooy et 
al. 2007; Daskalopoulou et al. 2016; O'Neil et al. 2016). More recently, research has transitioned to 
evaluating not only risk of developing CVD, but has turned its focus to promoting and maintaining 
cardiovascular health (CVH). In contrast with standard CVD risk predictors, which rely on non-modifiable 
demographic factors such as age, sex, and race (e.g., Goff et al. 2014), the 2010 American Heart 
Association (AHA) guidelines for CVH place less emphasis on non-modifiable factors and focus instead 
on modifiable lifestyle factors. The seven components of CVH include body weight, blood glucose, total 
cholesterol, blood pressure, physical activity, diet, and smoking status (Lloyd-Jones et al. 2010), where 
healthier values of each metric contribute to better (higher) CVH. Beyond the extensive body of research 
demonstrating an association between depression and increased risk of incident and recurrent CVD, 
studies are needed to evaluate whether there is also an association between depression and CVH. 
 Cross-sectional studies have found that adults with depressive symptoms are nearly 2.5 times 
more likely to have poor, rather than ideal, CVH (Szlejf et al. 2018). However, patterns of depressive 
symptoms are known to vary widely across the lifespan (Musliner et al. 2016). For some, depressive 
symptoms may be persistent, while others may go through periods of depression that later resolve. 
These distinct patterns have been shown to differentially affect physical, psychological, and social 
functioning, including some cardiovascular-related outcomes (Byers et al. 2012). Together, these 
findings indicate that it is relevant to evaluate patterns of depressive symptoms to best understand how 
timing and severity of depressive symptoms may influence CVH. No studies have yet evaluated 
longitudinal patterns of depression with CVH outcomes. 
Many argue that the associations between depression and cardiovascular outcomes can be 
explained by behavioral factors. For example, depression and smoking are highly comorbid, current and 
former smokers are more likely to experience depression, and smokers with depression tend to smoke 
more heavily than smokers without depression (A. E. Taylor et al. 2014; Pratt and Brody 2010). The 
associations between depression and smoking have been shown to be longitudinal and bidirectional 
(Chaiton et al. 2009). There is significant overlap in the mechanisms by which depression and smoking 
are hypothesized to negatively impact CVH (e.g., via inflammatory processes; Penninx 2017; USDHHS 
2010). In addition, we previously demonstrated that comorbid exposure to depressive symptoms and 
cigarette smoking accumulated during the lifespan among otherwise healthy adults had a synergistic 
association with risk of subclinical CVD (Carroll et al. 2017b), suggesting that smoking exposure may also 
moderate the influence of depressive symptom patterns on CVH.  
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No studies have specifically evaluated the potential interaction between depression and 
smoking with CVH. The purpose of the present study was to evaluate whether patterns of exposure to 
depressive symptoms over 20 years predicted CVH in middle adulthood, and whether patterns of 
exposure to smoking moderated this association. To identify distinct patterns of exposure, we used 
group-based trajectory modeling (Jones and Nagin 2007; Jones et al. 2001), an application of discrete 
mixture modeling designed to identify clusters of individuals who follow a similar progression of 
behavior over time. These patterns allowed us to determine acceleration (increase), deceleration 
(decrease), and rates of change (trends) in behaviors of interest, and to examine whether these patterns 
are differentially associated with CVH outcomes. We hypothesized that adults with patterns of high or 
increasing depressive symptoms and patterns of high or increasing smoking from young to middle 
adulthood (Year 0 to Year 20) would have synergistically poorer CVH at Year 20 (i.e., lower prevalence of 
AHA’s healthy lifestyle factors), beyond the individual additive effects of greater exposure to depressive 
symptoms and smoking, compared to adults with patterns of low or decreasing depressive symptoms, 
smoking, or both. We further examined this relationship exclusively among ever-smokers, with the 
similar hypothesis that ever-smokers with patterns of high or increasing depressive symptoms and 
patterns of high or increasing smoking from young to middle adulthood would have synergistically 
worse CVH at Year 20. 
Methods 
Study and sample description  
 The Coronary Artery Risk Development in Young Adults (CARDIA) study 
(http://www.cardia.dopm.uab.edu/) is an ongoing longitudinal, community-based cohort study 
designed to evaluate the development of coronary heart disease risk factors during young adulthood. In 
1985-1986 (Year 0), 5,115 young adults aged 18-30, who had permanent residence in the recruitment 
area and were in good health, were recruited from four United States cities (Cutter et al. 1991). 
Participants were recruited by telephone using census tracts, random digit dialing, health plan data, and 
household rosters; further details of recruitment and retention strategies have been published 
elsewhere (Hughes et al. 1987). Recruitment was stratified on sex, race (Black and White), age (18-24 
years and 25-30 years), education (≤ high school graduate and > high school graduate), and study site 
(Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland, CA). Follow-up exams were conducted at 
Year 2 (N=4,624, ages 20-32), 5 (N=4,352, ages 23-35), 7 (N=4,086, ages 25-37), 10 (N=3,950, ages 28-
40), 15 (N=3,672, ages 33-45), 20 (N=3,547, ages 38-50), 25 (N=3,499, ages 43-55), and 30 (N=3,358, 
ages 48-60). Because the dietary data required to assess CVH were only collected at Year 20 (see 
Measures: CVH assessment below), only data from Year 0 through Year 20 were included in this 
secondary data analysis. All procedures were IRB approved at each of the study sites, and informed 
consent was completed by each participant at each exam. 
Measures 
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 Depressive symptoms. Depressive symptoms were assessed by the Center for Epidemiologic 
Studies Depression scale (CES-D; Radloff 1977) at Years 5, 10, 15, and 20. The CES-D is a 20-item, self-
report, global measure of depressive symptoms over the past two weeks. Each symptom is assessed on 
a scale from 0 (never) to 3 (nearly every day), with total scores ranging from 0 (none/low depressive 
symptoms) to 60 (high depressive symptoms). Scores ≥16 points are considered to be clinically elevated 
symptoms.  
 Smoking. Smoking was queried at each exam (Years 0, 2, 5, 7, 10, 15, and 20), including current 
smoking status (≥5 cigarettes/week, almost every week) and, if participants indicated that they were a 
current smoker at any exam, they were then queried as to the average number of cigarettes per day 
(CPD) they smoked. Participants who attended an exam but reported that they were not currently 
smoking were noted as smoking 0 CPD for that exam. Some analyses were restricted to ever-smokers, 
defined as participants who reported current smoking at one or more exams. 
 CVH assessment. The AHA CVH Score is a clinical assessment of CVH comprising seven health 
metrics (body weight, blood glucose, total cholesterol, blood pressure, physical activity, diet, and 
smoking status) (Lloyd-Jones et al. 2010). Though distinct from CVD risk profiles (e.g., Goff et al. 2014), 
the CVH score is inversely associated with fatal and non-fatal CVD events (Fang et al. 2016). Each 
component is scored as poor (0), intermediate (1), or ideal (2), yielding an overall score between 0 and 
14 (Huffman et al. 2012). This score has been used to evaluate associations between CVH and 
psychosocial variables, including depressive symptoms (e.g., Szlejf et al. 2018). For the present analyses, 
because smoking was included as a predictor variable, a modified score was calculated without smoking 
status for total scores ranging from 0 to 12, where higher scores reflect greater CVH (i.e., greater 
adherence to healthy lifestyle factors). In sensitivity analyses, the CVH Score was calculated with 
smoking status (presented in the Electronic Supplementary Material: Methods, Table 1). 
 Body weight. BMI was calculated from the physical exam measurements of weight in kilograms 
divided by height in meters squared (kg/m2). The AHA thresholds for the CVH BMI score are: (0) Poor= 
≥30 kg/m2, (1) Intermediate= ≥25 and <30 kg/m2, and (2) Ideal= <25 kg/m2. BMI was not calculated for 
participants who were pregnant at the time of the exam. 
 Blood glucose. Glycemic status was assessed by fasting blood glucose [FBG] or hemoglobin A1c 
[HbA1c] levels, self-reported diagnosis of diabetes mellitus, and use of glucose-lowering medications. 
Participants were instructed to fast for 12 hours and avoid smoking and heavy physical activity for at 
least 2 hours prior to the exam. FBG was measured by the hexokinase-ultraviolet method. HbA1c was 
measured by the high-performance liquid chromatography method. The AHA thresholds for the CVH 
glucose score are: (0) Poor= FBG ≥7 mmol/L, HbA1c ≥48 mmol/mol, or diagnosed with diabetes mellitus 
(or using medications) with HbA1c ≥53 mmol/mol; (1) Intermediate= FBG ≥5.6 mmol/L and <7 mmol/L, 
HbA1c ≥39 mmol/mol and <48 mmol/mol, or diagnosed with diabetes mellitus (or using medications) 
with HbA1c <53 mmol/mol; and (2) Ideal= FBG <5.6 mmol/L, HbA1c <39 mmol/mol, and not diagnosed 
with diabetes mellitus (and not using medications). 
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 Total cholesterol. Total cholesterol was determined by enzymatic procedures using the ABA 
Biochromatic instrument (Warnick 1986) following 12 hours of fasting and at least 2 hours avoiding 
smoking and heavy physical activity. The AHA thresholds for the CVH cholesterol score are: (0) Poor= 
total cholesterol ≥240 mg/dL or treated total cholesterol ≥200 mg/dL, (1) Intermediate= total 
cholesterol ≥200 mg/dL and <240 mg/dL or treated total cholesterol <200 mg/dL, and (2) Ideal= 
untreated total cholesterol <200 mg/dL. 
 Blood pressure. Three seated blood pressure (BP; mmHg) measurements were taken after a 5-
minute resting period and the 2nd and 3rd readings were averaged. The AHA thresholds for the CVH BP 
score are: (0) Poor= untreated or treated systolic blood pressure (SBP) ≥140 mmHg or diastolic blood 
pressure (DBP) ≥90 mmHg, (1) Intermediate= untreated SBP ≥120 mmHg and <140 mmHg or DBP ≥80 
mmHg and <90 mmHg, or treated SBP <140 mmHg and DBP <90 mmHg, and (2) Ideal= untreated SBP 
<120 mmHg and DBP <80 mmHg. 
 Physical activity. The AHA thresholds for the CVH physical activity score are: (0) Poor= no 
leisure-time physical activity (<1 minute/week), (1) Intermediate= ≥1 and <150 minutes/week of 
moderate intensity or ≥1 and <75 minutes/week of vigorous intensity physical activity, and (2) Ideal= 
≥150 minutes/week of moderate intensity or ≥75 minutes/week of vigorous intensity physical activity. In 
CARDIA, participants completed the physical activity history (PAH) questionnaire, which queries the 
average amount of time spent engaging in various light, moderate, and vigorous intensity physical 
activities from which a calculation of “exercise units” (EU) is derived (Jacobs et al. 1989). A direct 
conversion from the PAH score to the AHA CVH physical activity score was not possible. For Ideal 
physical activity, ≥300 EU that has been found to be a valid threshold for adults meeting physical activity 
guidelines (Gabriel et al. 2014). For Intermediate physical activity, we chose a threshold higher than 0 EU 
because the PAH score includes light intensity activities whereas the AHA CVH Score is calculated only 
from moderate and vigorous intensity activities. Therefore, the thresholds for the modified physical 
activity score were: (0) Poor= <150 EU, (1) Intermediate= ≥150 EU and <300 EU, and (2) ≥300 EU. 
 Diet. The AHA diet recommendations include 5 measures, including ≥4.5 cups/day of 
fruits/vegetables, ≥2 servings (3.5 oz) of fish per week (3.5-oz servings), <1500 mg/day of sodium, <450 
kcal (36 oz)/week of sweets/sugar-sweetened beverages, and ≥3 servings/day of whole grains. 
Participants completed CARDIA Diet History Interview, from which we derived the diet scores consistent 
with AHA thresholds, as has been done previously (Liu et al. 1994; McDonald et al. 1991). The thresholds 
for the AHA CVH diet score were: (0) Poor= meeting 0 or 1 of the AHA diet recommendations, (1) 
Intermediate= meeting 2 or 3 of the AHA diet recommendations, and (2) Ideal= meeting 4 or 5 of the 
AHA diet recommendations. 
Data analysis  
 All analyses were conducted using SAS, Version 9.4. A threshold of p<.05 (two-sided) was used 
to determine statistical significance.  
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Trajectory modeling. We used latent class models (fitted by SAS Proc Traj; Jones and Nagin 2007; 
Jones et al. 2001) to model the developmental trajectories for 1) CES-D scores in the full sample, 2) CPD 
in the full sample, 3) CES-D scores among smokers, and 4) CPD among smokers. CES-D score trajectories 
used data from Years 5, 10, 15, and 20 using the censored normal (CNORM) model. CPD trajectories 
used data from Years 0, 2, 5, 7, 10, 15, and 20 using the zero-inflated Poisson (ZIP) model due to the 
large proportion of 0-values. We analyzed trajectory models with 2 through 10 groups, and model fit 
was assessed using the Bayesian Information Criterion (BIC) and the Akaike Information Criterion (AIC), 
as recommended (Nagin et al. 2016; Niyonkuru et al. 2013). The optimal number of trajectory groups is 
determined when the BIC and AIC were maximized or when adding more groups did not substantially 
differentiate between trajectory patterns. We then qualitatively assessed the trajectory patterns and 
determined whether the patterns were clinically meaningful (i.e., unique and interpretable patterns that 
follow observed population trends). We first ran each model with a cubic function; however, the CES-D 
trajectories did not reach a global maximum until we assigned lower polynomial function (quadratic). 
Next, because trajectory models often find only the local maximum (as opposed to the global maximum) 
when using default start values, we ran each model using the recommended start parameters and 
polynomial function for each trajectory group to achieve a model that reached a global maximum (i.e., 
best-fit polynomial function for each trajectory group within the trajectory model; Jones and Nagin 
2007). The posterior predictive probability of group membership was calculated for each model, and 
participants were assigned to the trajectory group for which they had the greatest posterior predictive 
probability. The average posterior predictive probabilities were assessed for adequacy of model fit (see 
Electronic Supplemental Material; Niyonkuru et al. 2013). Finally, we named each trajectory group based 
on qualitative examination of the patterns of depression and smoking. 
Missing data. No missing data were imputed for the present analysis. Trajectory modeling 
allows all participants with at least one measure at any exam to be categorized in the trajectory model. 
As a result, no participants were excluded from the present analysis due to missing CES-D or CPD data. 
Likewise, because the covariates included in all models were collected at baseline, none of these data 
were missing. 
Of the 5,115 participants enrolled in CARDIA, 442 (9%) did not complete the CES-D at any exam 
and were excluded from the trajectory analyses. Of 4,672 participants with complete trajectory data, 
1,586 (34%) were missing data on one or more of the CVH measures at Year 20: 1,154 on body weight, 
1,177 on blood glucose, 1,124 on cholesterol, 1,132 on blood pressure, 1,151 on physical activity, and 
1,532 on diet.  
Of the 2017 CARDIA participants who reported any smoking history (ever-smokers), 190 (9%) 
were missing data on the CES-D. Of 1,827 ever-smokers with complete trajectory data, 739 (40%) were 
missing data on one or more of the CVH measures at Year 20: 568 on body weight, 659 on blood 
glucose, 553 on cholesterol, 560 on blood pressure, 568 on physical activity, and 719 on diet. 
 Primary analyses. Generalized linear models (GLM) were used to examine the associations 
between CES-D trajectory, CPD trajectory, and the CES-D trajectory x CPD trajectory interaction with 
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CVH Score at Year 20. To ensure that power to detect an interaction in a 5x5 interaction analysis was 
preserved, the analyses were also run with the trajectory group variables entered as continuous 
measures ranked by increasing levels of exposure. For models with a non-significant interaction term, 
the interaction term was removed and the main effects of CES-D trajectory or CPD trajectory were 
examined. As noted above, all models were also completed with the CVH Score calculated with smoking 
status (see Electronic Supplementary Material). Adjusted models included sociodemographic 
covariates: sex (male, female), race (White, Black), age (years), and educational attainment (years). 
Results 
Sample characteristics 
 The 3,086 participants with complete data for analyses in the full sample comprised 57% female, 
46% Black, and were 45 years of age (SD=3.6 years) with 15 years of education (SD=2.6 years) at Year 20. 
Participants excluded from the analysis were more likely to be male (49%), black (59%), have fewer 
years of education (M=14 years, SD=2.5), reported modestly higher depressive symptoms when 
available (between 1 and 2 points on the CES-D), and were more likely to be smokers. 
The 1,088 ever-smokers with complete data for analysis comprised 56% female, 53% Black, and 
were 45 years of age (SD=3.6 years) with 14 years of education (SD=2.4 years) at Year 20. Reflective of 
the full sample, ever-smokers excluded from the analysis were more likely to be male (52%), black 
(63%), and have fewer years of education (M=13 years, SD=2.3), but they did not differ in CES-D scores 
or CPD. 
The prevalence rates for each CVH Score component (BMI, blood glucose, cholesterol, blood 
pressure, physical activity level, and diet) in the full sample and among smokers are presented in Table 
1. The CVH Scores ranged from 0 to 12, with a mean CVH Score of 7.2 (SD=2.2) in the full sample and 7.0 
(SD=2.1) among ever-smokers.  
Trajectory models 
 The final trajectory models are presented in Figure 1. All trajectory models were best fit using a 
5-group model. For CES-D scores in the full sample (Figure 1a), the model included trajectories 
characterized by consistently low scores (“no depression,” 57%), persistently moderate scores <16 
(“subthreshold depression,” 30%), initially high scores that decreased to subthreshold levels 
(“decreasing depression,” 4%), initially subthreshold scores that increased (“increasing depression,” 8%), 
and persistently high scores (“high depression,” 1%). Among smokers (Figure 1b), the CES-D trajectories 
revealed similar patterns of no depression (51%), subthreshold depression (29%), decreasing depression 
(5%), increasing depression (12%), and high depression (2%). 
 For CPD in the full sample (Figure 1c), the model included trajectories characterized by 
consistent 0 CPD (“nonsmokers,” 55%), initial light smoking around 5 CPD that decreased to nearly 0 by 
Year 5 (“quitters,” 14%), smoking that decreased over time from 10 CPD to 5 CPD (“light smokers,” 15%), 
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smoking that decreased over time from 15-20 CPD to 10 CPD (“moderate smokers,” 12%), and 
persistent, heavy smoking that started at 30-35 CPD and decreased over time to 15-20 CPD (“heavy 
smokers,” 3%). Among smokers (Figure 1d), CPD trajectories were characterized by <5 CPD that 
decreased to near-0 CPD (“quitters,” 13%), persistent light smoking around 5 CPD (“light smokers,” 
24%), persistent smoking around 10 CPD that decreased to around 5 CPD (“moderate smokers,” 31%), 
persistent smoking that decreased from around 20 CPD to between 15 CPD (“heavy smokers,” 25%), and 
persistent smoking that decreased from 30-35 CPD to 20-25 CPD (“very heavy smokers,” 7%).  
CES-D trajectory x CPD trajectory and modified AHA CVH Score 
 The mean (standard deviation) CVH Score by each trajectory group are presented in Electronic 
Supplementary Material: Table 3. In the GLM, the CES-D trajectory x CPD trajectory interactions were 
not significant for either model predicting CVH Score at Year 20 (full sample pinteraction=.374; smokers 
pinteraction=.473; full model results presented in Table 2). When the trajectory groups were entered as a 
continuous variable, we still did not find a significant interaction between the CES-D trajectory x CPD 
trajectory in either the full sample (pinteraction=.299) or among smokers (pinteraction=.430). 
 After removing the non-significant interaction terms, we observed main effects of both CES-D 
trajectory (p<.001) and CPD trajectory (p<.001) in the full sample (full model results presented in Table 
3). Compared to participants in the no depression group (lsmean=7.23), CVH scores were lower among 
participants in the subthreshold depression group (lsmean=6.96), increasing depression group 
(lsmean=6.71), and high depression group (lsmean=6.58); the difference between the no depression 
group and the decreasing depression group (lsmean=7.02) did not reach statistical significance. Among 
CPD trajectories, only those in the heavy smokers group (lsmean=6.47) had significantly lower CVH 
Scores than those in the nonsmokers group (lsmean=6.96), while those in the quitters group 
(lsmean=7.34) had significantly higher CVH Scores; differences between nonsmokers and light smokers 
(lsmean=6.96) and moderate smokers (lsmean=6.78) did not reach statistical significance.  
 Among smokers, there was not a main effect of CES-D trajectory (p=.107) but we did observe a 
main effect of CPD trajectory (p<.001). There was an inverse dose-dependent association between CPD 
trajectory and CVH Score, where compared to quitters (lsmean=7.45), CVH Scores were lower with 
greater exposure (moderate smokers lsmean=6.76; heavy smokers lsmean=6.65; very heavy smokers 
lsmean=6.14); CVH Scores were not significantly lower among light smokers (lsmean=7.27) compared to 
quitters.  
Discussion 
Contrary to our hypothesis, the interactions between patterns of depressive symptoms and 
patterns of smoking from young- to middle-adulthood were not synergistically associated with CVH in 
middle-adulthood previously among healthy, community-dwelling adults. This finding contrasts with 
studies demonstrating that depressive symptoms and smoking interact to convey increased risk for 
developing CVD (Rutledge et al. 2012; Carroll et al. 2017b). However, we observed interesting main 
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effects of patterns of depressive symptoms and patterns of smoking. Generally, greater exposure to 
either depressive symptoms or smoking independently over 20 years was associated with poorer CVH, 
as assessed by a composite measure based on the AHA’s definition of modifiable lifestyle factors 
(Huffman et al. 2012). These findings may suggest that differential patterns of depressive symptoms and 
smoking matter less than total, cumulative exposure to these risk factors for maintaining and promoting 
CVH.  
 The CARDIA study allowed us to examine longitudinal patterns of depressive symptoms and 
smoking from young- to middle-adulthood among mostly disease-free individuals with CVH outcomes. 
Nonetheless, the following discussion should be considered within the context of some limitations. First, 
as noted above, some of the AHA CVH Score calculations had to be adapted for the CARDIA dataset, 
which limits our interpretation of CVH and comparisons with results of other studies using the AHA CVH 
Score. Second, we were constrained by the available data for this secondary analysis, including limited 
information regarding psychiatric history and antidepressant treatment. Third, discussion of the present 
results within the context of the available literature is limited by variability in the measurement of 
depression and depressive symptoms, which has been shown to affect the strength of the associations 
between depression and CVD risk (Nicholson et al. 2006). Therefore, when possible, the following 
discussion is limited to those studies with measurement constructs that were similar to those used in 
the present study. Finally, the lack of an interactive effect between depressive symptoms and smoking 
may be reflective of limited power to detect an interaction in the present analysis, although sensitivity 
analyses with the trajectory variables entered continuously to preserve power also did not detect a 
significant interaction. 
In the main effects analyses, we observed an association between patterns of elevated 
depressive symptoms (subthreshold depression, increasing depression, and high depression) and worse 
CVH in the full sample in a dose-dependent manner; those with decreasing depression did not differ 
significantly from those without depression. In other words, those with greater exposure to depression 
had poorer adherence to healthy lifestyle factors comprising CVH. This pattern was similarly observed in 
a study which found that, although depressive symptoms among adolescents was associated with 
greater risk of physical health problems during adolescence and young adulthood, those participants 
whose adolescent-stage depressive symptoms resolved then had lower risk of physical health problems 
during young adulthood (Ames and Leadbeater 2018). These results suggest that the physical impact of 
depressive symptoms may be reversible, particularly with early identification and treatment. It is also 
possible that the groups with decreasing or increasing depressive symptoms in the present study were 
too small to detect a significant difference from those without depression.  
A small number of studies have also found that individuals with psychological conditions, 
including depression, have poorer CVH as assessed by the adherence to the AHA CVH guidelines of 
modifiable lifestyle factors (Veromaa et al. 2017; Kronish et al. 2012; Espana-Romero et al. 2013; Li et al. 
2015; Gaye et al. 2016), and numerous studies have established an association between depression and 
incidence and prevalence of CVD (e.g., cardiac events; Mathur et al. 2016), early CVD conditions (e.g., 
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cholesterol; Davidson et al. 2000; Shin et al. 2008), and other CVD risk conditions (e.g., diabetes; Rotella 
and Mannucci 2013). In one study among middle-aged adults in Korea using latent growth trajectory 
modeling of depressive symptoms, trajectories of high depressive symptoms were associated with 
greater prevalence of metabolic abnormalities over an average of 4 years of follow-up, even after 
accounting for smoking (Kim et al. 2015). Overall, however, few studies have evaluated patterns of 
exposure to depressive symptoms with CVH outcomes, which may reveal important information 
regarding the timing and severity of this risk condition.  
 A consideration for future studies is that certain clusters of depressive symptoms (e.g., somatic 
symptoms), rather than a global assessment, may have a greater influence on CVH compared to others, 
as has been frequently demonstrated among patients with CVD (Baune et al. 2012). A 2017 analysis of 
CARDIA evaluating the interaction between depressive symptom clusters and smoking found that only 
somatic symptoms of depression significantly interacted with smoking exposure to predict greater odds 
of CAC (Carroll et al. 2017a), while a 2012 analysis of CARDIA found that the negative affect cluster was 
associated with risk of developing CAC more so than somatic symptoms or other symptom clusters 
(Stewart et al. 2012). Fewer studies have examined this association with incident CVD, but a 2014 study 
demonstrated that somatic symptoms of depression were associated with incident CAD events (Hawkins 
et al. 2014). Future studies may also find that specific depressive symptoms are more robustly 
associated with CVH. 
 We also observed a main effect of smoking patterns in the full sample. First, compared to never 
smokers, quitters had significantly better CVH (i.e., greater prevalence of adherence to modifiable 
lifestyle factors). Of course, it is well established that quitting smoking can lower one’s blood pressure 
and cholesterol levels and improve diabetes management (USDHHS 2014), all factors assessed in the 
CVH Score. Conversely, those who quit smoking often gain weight (Aubin et al. 2012) which would 
decrease CVH, although this outcome varies widely and may not have been substantial enough to affect 
a participant’s BMI categorization. Adults who quit smoking are more physically active and, moreover, 
the disparity in physical activity levels between those who quit smoking and those who continue 
smoking increases over time (Auer et al. 2014). In addition, quitting smoking has been associated with a 
lower prevalence of psychiatric conditions, including depression (Piper et al. 2013; G. Taylor et al. 2014), 
which likely also contributes to improved health behaviors and overall improvements in CVH 
components, even compared to those who never smoked.  
Second, among smokers, greater smoking exposure was associated with worse CVH in a dose-
dependent manner compared to never smokers. These findings support public health warnings that 
continuing to smoke, even at low rates, will adversely affect physical health (USDHHS 2014). Aside from 
the risk directly attributable to smoking, current smoking is also associated with poor health behaviors 
comprising CVH as well as other lifestyle factors that adversely affect CVD, such as low medication 
adherence (Kamran et al. 2014; Al AlShaikh et al. 2016), lower physical activity levels and more time 
spent sedentary (Noble et al. 2015; Kaczynski et al. 2008), and greater prevalence of substance use and 
psychiatric disorders (Morisano et al. 2009; Chou et al. 2016). Public health efforts are warranted to 
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continue to deter smoking initiation, as are both individual and population-level interventions to help 
current smokers quit. 
 Based on our findings, it does not appear that relationship between depression and CVH is 
moderated by smoking status. It remains possible that other risk behaviors, such as a sedentary lifestyle, 
limited physical activity, or poor diet, or a combination of behavioral factors, are mechanisms through 
which depression influences CVH (Liu et al. 2017; Penninx 2017). It has also been hypothesized that 
depression negatively impacts CVH via other treatable cardiovascular and metabolic conditions (Hackett 
and Steptoe 2016; Kim et al. 2015). A recent study with over 10,000 healthy adults followed for 20 years 
similarly did not find that depressive symptoms significantly interacted with hypertension, dyslipidemia, 
or diabetes, to predict cardiac events (Hamieh et al. 2018). The nature of the relationships between 
depression, treatable cardiovascular conditions, and maintaining CVH remains an area for future 
research. 
There are also studies demonstrating that depression is accompanied by physiological changes 
in the body, which may lead to CVD. One of the most prominent is the inflammation hypothesis of 
depression (Berk et al. 2013). In fact, in a previous analysis, we found that the high exposure and 
increasing patterns of depressive symptoms were associated with inflammation, independent of the 
smoking patterns (Carroll et al. 2019; Epub ahead of print). Others have shown that the combination of 
depressive symptoms and inflammation, more than either factor alone, was associated with greater risk 
of CVD-related mortality among men (Lawes et al. 2018), suggesting the relationship between 
depressive symptoms and inflammation may be additive rather than mechanistic. There is also evidence 
for reverse causation, where individuals with other CVD risk factors have been shown to be at risk of 
depression later in life (Armstrong et al. 2017; Patel et al. 2018). Further studies are needed to fully 
elucidate the mechanism by which depression increases risk for CVD in order to treat these at-risk 
individuals and preserve CVH. 
 The AHA has recently increased its focus on CVH maintenance and promotion, as assessed using 
modifiable lifestyle factors. In contrast with previous findings of CVD risk development (Carroll et al. 
2017b), we did not find that specific patterns of depressive symptoms and smoking had synergistic 
associations with CVH, as assessed by a composite score of healthy lifestyle factors consistent with the 
AHA guidelines for CVH (Huffman et al. 2012; Lloyd-Jones et al. 2010). These results suggest that the 
interaction between depressive symptoms and smoking may be more robust for CVD development than 
for CVH maintenance. Independently, greater exposure to depressive symptoms and cigarette smoking 
throughout young- to middle-adulthood were associated with worse CVH, particularly those with higher 
levels of ongoing exposure to these risk factors. Thus, the pattern of exposure to depression, smoking, 
and their co-occurrence may be less relevant than total, cumulative exposure over time.  
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Table 1. Prevalence of modified AHA CVH Score components by score at Year 20: CARDIA, 2005-2006 
  Full sample (N=3086) Ever-smokers (N=1088)  
CVH Component N (%) N (%) 
BMI         
2 880 (29%) 306 (28%) 
1 1035 (34%) 369 (34%) 
0 1171 (38%) 413 (38%) 
Blood glucose         
2 1812 (59%) 621 (57%) 
1 1065 (35%) 379 (35%) 
0 209 (7%) 88 (8%) 
Total cholesterol         
2 1760 (57%) 619 (57%) 
1 1171 (38%) 406 (37%) 
0 155 (5%) 63 (6%) 
Blood pressure         
2 1804 (58%) 588 (54%) 
1 1034 (34%) 388 (36%) 
0 248 (8%) 112 (10%) 
Physical activity         
2 1424 (46%) 478 (44%) 
1 742 (24%) 273 (25%) 
0 920 (30%) 337 (31%) 
Diet         
2 142 (5%) 38 (3%) 
1 1627 (53%) 494 (45%) 
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0 1317 (43%) 556 (51%) 
The thresholds for the modified AHA CVH Score assignment for each component are as follows, where 
higher scores indicate better CVH: BMI score 2: <25 kg/m2, 1: 25-30 kg/m2, 0: >30 kg/m2. Blood glucose 
score 2: FBG<7 mmol/L, HbA1c <38 mmol/mol, and not diagnosed with diabetes; 1: FBG 5.6-7 mmol/L, 
HbA1c 39-48 mmol/mol, or HbA1c <53 mmol/mol and diagnosed with diabetes; 0: FBG ≥7 mmol/L, 
HbA1c ≥48 mmol/mol, or HbA1c ≥53 mmol/mol and diagnosed with diabetes. Total cholesterol score 2: 
untreated <200 mg/dL; 1: untreated 200-239 mg/dL or treated <200 mg/dL; 0: untreated >240 mg/dL or 
treated >200 mg/dL. Blood pressure score 2: <120/<80 mmHg; 1: 120-139/80-90 mmHg; 0: >140/>90 
mmHg. Physical activity score 2: ≥300 EU; 1: ≥150 EU and <300 EU; 0: <150 EU. Diet score 2: 4-5 diet 
recommendations; 1: 2-3 diet recommendations; 0: 0-1 diet recommendations.  
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Table 2. Models predicting modified AHA CVH Score at Year 20 based on trajectories of depressive 
symptoms, smoking, their interaction, and covariates (Years 0 to 20): CARDIA, 1985-2006 
Variable Estimate 95% CI p-value 
Full sample (N=3086)         
Intercept 9.44 (8.41 10.47) <.001 
Sex (female) -0.31 (-0.46 -0.17) <.001 
Race (Black) -1.23 (-1.39 -1.07) <.001 
Age -0.07 (-0.09 -0.05) <.001 
Education 0.12 (0.09 0.15) <.001 
CES-D trajectory (ref: no depression) 
   
0.103 
   Subthreshold depression -0.34 (-0.56 -0.12) 0.003 
   Decreasing depression -0.38 (-0.91 0.15) 0.164 
   Increasing depression -0.94 (-1.38 -0.51) <.001 
   High depression -0.14 (-1.10 0.83) 0.783 
CPD trajectory (ref: nonsmokers) 
   
0.049 
   Quitters 0.29 (0.00 0.57) 0.051 
   Light smokers -0.21 (-0.49 0.08) 0.152 
   Moderate smokers -0.19 (-0.52 0.13) 0.238 
   Heavy smokers -0.61 (-1.20 -0.03) 0.040 
CES-D x CPD 
   
0.374 
Among smokers (N=1088)         
Intercept 10.49 (8.80 12.17) <.001 
Sex (female) -0.15 (-0.39 0.08) 0.206 
Race (Black) -1.14 (-1.40 -0.88) <.001 
Age -0.07 (-0.11 -0.04) <.001 
Education 0.08 (0.03 0.14) 0.002 
CES-D trajectory (ref: no depression) 
   
0.178 
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   Subthreshold depression -0.09 (-0.80 0.61) 0.796 
   Decreasing depression -0.29 (-2.02 1.44) 0.745 
   Increasing depression -1.01 (-2.50 0.47) 0.181 
   High depression -2.89 (-5.58 -0.20) 0.035 
CPD trajectory (ref: quitters) 
   
<.001 
   Light smokers -0.43 (-0.98 0.11) 0.119 
   Moderate smokers -0.75 (-1.26 -0.24) 0.004 
   Heavy smokers -0.66 (-1.20 -0.12) 0.018 
   Very heavy smokers -1.37 (-2.11 -0.62) 0.000 
CES-D x CPD       0.473 
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Table 3. Models predicting modified AHA CVH Score at Year 20 based on trajectories of depressive 
symptoms, smoking, (interaction term removed), and covariates (Years 0 to 20): CARDIA, 1985-2006 
Variable Estimate 95% CI p-value 
Full sample (N=3086)         
Intercept 9.37 (8.35 10.40) <.001 
Sex (female) -0.31 (-0.45 -0.16) <.001 
Race (Black) -1.23 (-1.38 -1.07) <.001 
Age -0.07 (-0.09 -0.05) <.001 
Education 0.12 (0.09 0.15) <.001 
CES-D trajectory (ref: no depression)  
  
<.001 
   Subthreshold depression -0.26 (-0.43 -0.10) 0.001 
   Decreasing depression -0.20 (-0.57 0.17) 0.281 
   Increasing depression -0.51 (-0.79 -0.23) <.001 
   High depression -0.65 (-1.27 -0.02) 0.042 
CPD trajectory (ref: nonsmokers)  
  
<.001 
   Quitters 0.38 (0.16 0.59) <.001 
   Light smokers 0.00 (-0.21 0.21) 0.976 
   Moderate smokers -0.18 (-0.41 0.05) 0.132 
   Heavy smokers -0.49 (-0.93 -0.06) 0.027 
Among smokers (N=1088)         
Intercept 10.41 (8.74 12.08) <.001 
Sex (female) -0.17 (-0.40 0.07) 0.169 
Race (Black) -1.12 (-1.38 -0.87) <.001 
Age -0.07 (-0.11 -0.04) <.001 
Education 0.09 (0.04 0.14) <.001 
CES-D trajectory (ref: no depression)  
  
0.107 
   Subthreshold depression -0.25 (-0.52 0.02) 0.069 
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   Decreasing depression 0.06 (-0.47 0.58) 0.835 
   Increasing depression -0.12 (-0.49 0.25) 0.533 
   High depression -0.89 (-1.69 -0.10) 0.028 
CPD trajectory (ref: quitters) 
   
<.001 
   Light smokers -0.18 (-0.58 0.22) 0.374 
   Moderate smokers -0.70 (-1.08 -0.31) <.001 
   Heavy smokers -0.81 (-1.21 -0.40) <.001 
   Very heavy smokers -1.32 (-1.88 -0.75) <.001 
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Figure Captions 
Fig. 1 
a. Trajectory model of CES-D scores, full sample (N=3,086). No depression (n=1762, 57%). Subthreshold 
depression (n=923, 30%). Decreasing depression (n=125, 4%). Increasing depression (n=234, 8%). High 
depression (n=42, 1%): CARDIA, 1990-2006 
 
b. Trajectory model of CES-D scores, among ever-smokers (N=1,088). No depression (n=555, 51%). 
Subthreshold depression (n=319, 29%). Decreasing depression (n=56, 5%). Increasing depression (n=134, 
12%). High depression (n=24, 2%): CARDIA, 1990-2006 
 
c. Trajectory model of cigarettes per day, full sample (N=3,086). Nonsmokers (n=1707, 55%). Quitters 
(n=440, 14%). Light smokers (n=466, 15%). Moderate smokers (n=382, 12%). Heavy smokers (n=91, 3%): 
CARDIA, 1985-2006 
  
d. Trajectory model of cigarettes per day, among ever-smokers (N=1,088). Quitters (n=137, 13%). Light 
smokers (n=261, 24%). Moderate smokers (n=341, 31%). Heavy smokers (n=274, 25%). Very heavy 
smokers (n=75, 7%): CARDIA, 1985-2006  
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